The rapid evolutionary dynamics of RNA viruses, driven by high mutation rates and the consequent formation of complex ...
Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...
Market valued at $28.67B in 2024, projected 5.10% CAGR growth driven by sustainable materials, e-commerce demands, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results